Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nektar Therapeutics
Headquarters: San Francisco, CA, United States of America
Website: http://www.nektar.com
Year Founded: 1990
Status: Public
Industry Sector: HealthTechnology
CEO: Howard W. Robin
Number Of Employees: 61
Enterprise Value: $130,378,730
PE Ratio: -1.13
Exchange/Ticker 1: NASDAQ:NKTR
Exchange/Ticker 2: N/A
Latest Market Cap: $122,642,504
BioCentury | Mar 24, 2025
Data Byte
Petrelintide up front shatters biotech deal record
At nearly $1.7B, Zealand got $300M more than the prior top cash payment
BioCentury | Dec 7, 2024
Data Byte
At $1B, PTC-Novartis deal ties record for cash up front
But partnership lands fourth on overall upfront payment
BioCentury | Apr 30, 2024
Deals
Deals Report: BMS-Repertoire to develop vaccines for autoimmunity
Plus: Regeneron, Mammoth to make CRISPR-based gene editing therapies, and updates from Vertex-TreeFrog, Ono-Deciphera and more
BioCentury | Jan 23, 2024
Management Tracks
Siga names Diem Nguyen CEO
Plus: Fish & Richardson names Sawert as principal and updates from ImmunoBrain and DiaMedica
BioCentury | Dec 7, 2023
Product Development
The first-in-human immuno-oncology problem
Companies face growing challenges in deciding whether to advance an immuno-oncology program based on early Phase I data
BioCentury | Nov 15, 2023
Deals
Alkermes oncology spinout Mural charts its future
Newly independent cancer biotech looks to twin 2025 readouts of IL-2 program that leads pipeline of engineered cytokine therapeutics
BioCentury | Aug 8, 2023
Deals
Aug. 7 Quick Takes: Eyeing cash, Ikena buys Pionyr
Plus: Astellas’ Zimura approved for geographic atrophy, Bavarian’s chikungunya vaccine heading to regulators and updates from Gracell, IO, Sage, Nektar and DotBio
BioCentury | Aug 4, 2023
Management Tracks
Karuna names new CFO and HR head
Plus: Freeman joins Zentalis as chief strategy officer, and updates from Complement,
BioCentury | Feb 24, 2023
Regulation
Feb. 23 Quick Takes: FDA approves Sanofi’s once-weekly hemophilia A therapy
Plus: CMS stays the course on Alzheimer's NCD and updates from Blueprint, Apellis, AZ, Nektar, Keymed, Prilenia and more
BioCentury | Feb 3, 2023
Management Tracks
Vessey to leave BMS in July
Plus: Nichols joining enGene as CEO and updates from Invivyd, Exai and more
Items per page:
1 - 10 of 533